Gedea receives funding from Horizon 2020
Gedea has been granted SEK 500,000 in appropriations from the SME Instrument phase 1 program within the EU Horizon 2020 framework program. The Horizon 2020 program is competitive and only a few percent of all grant applications are granted.
Gedea starts clinical trial
Gedea has received approval from the Swedish Medical Products Agency the first clinical study Last week, the Medical Products Agency and Ethics Committee announced that they approved Gedea's first clinical study. The study is an important step towards CE marking of pHyph, which is a completely new…
Gedea in the finals of European Health Catapult
Gedea Biotech has reached the final at European Health Catapult, a European startup competition. In tough competition by really strong companies, Gedea went on to the final in Lodz in December. Out of the 14 who reached to the semifinal, seven went on and Gedea is one of them. Another company from…
Gedea winner in NLS Days Start Up Challenge
Last Wednesday, Gedea Biotech won a shared first place and Akuru Pharma a third, in the pitch competition "Startup Challenge" at NLSDays, the…
Gedea och Akuro i topp
12 september 2018 I onsdags kom Gedea Biotech på en delad förstaplats och Akuru Pharma på en tredjeplats i pitchtävlingen ” Startup Challenge” vid NLSDays, Nordens största partneringmässa inom life science. Det är andra året i rad som SmiLe-bolag tar topplaceringar i tävlingen. Läs hela…
Gedea in Serendipity Challenge final in Almedalen
Gedea Biotech has reached the finals in Serendipity Challenge that is an annual entrepreneurship competition and tech venue open to all Swedish and Nordic startups and growth companies. The competition final takes place during Almedalsveckan (2-4 July) where 50 of the most innovative and promising…
The antimicrobial resistance issue requires many small solutions
Today, Rapidus draws attention to the problem of antimicrobial resistance and the challenge of more and more antibiotics becoming ineffective. Gedea Biotech's forthcoming treatment is mentioned as a solution, among others, which will make us less dependent on antibiotics. Read full article
Gedea Biotech has received 1 MSEK for clinical study for CE mark of new product
Smile Company Gedea Biotech has received 1 MSEK in Vinnova funding in Swelife and MedTech4Health's joint announcement "Project for better health". The money will finance the first clinical trial in patients with vaginal fungal infection. Read more
CEO on Rapidus´list over talent from Skåne
Rapidus made a list of talented young professionals in the business environment in Skåne "that Stockholm based media missed". On the list is Annette Säfholm, CEO of Gedea Biotech. Read full article here.
Gedea Biotech receives Vinnova financing and strengthens the board
Gedea Biotech has been granted 900.000 SEK in Vinnova's grant program for innovative startup companies. The company has also expanded the board with Mats Persson, who has over 30 years of experience in marketing and sales in life sciences. The recruitment means a valuable strengthening of the…